MSD Animal Health's Needle-Free Intradermal Vaccine Porcilis® Circovac® Receives Approval in China

Shanghai, China, January 10, 2025——MSD (MSD is the trade name of Merck & Co., Inc., located in Rahway, New Jersey, USA) announced today that its Animal Health Division has developed a needle-free intradermal immunization vaccine for Porcine Circovirus Type 2 (recombinant baculovirus BacPCV2-Orf2 strain) (Brand name: Bao Zhu Li).^®Yuan Le Da^®) (hereinafter referred to as Yuanleda^®) has recently been approved by China's Ministry of Agriculture and Rural Affairs for the prevention of diseases related to Porcine Circovirus Type 2 infection. It is the first needle-free intradermal immune vaccine to be successfully approved in China.

       Needle-Free Intradermal Immunization Technology (IDAL)^®) originated from MSD Animal Health's exploration of new immunization pathway technologies in Europe more than 30 years ago. By using electrically driven compressed air, along with specially developed intradermal vaccines, each dose requires only 0.2ml to present the vaccine’s antigen through dendritic cells in the dermal tissue, thereby stimulating the body's immune response and generating specific protective immunity against certain diseases.

       Compared with traditional intramuscular immunization vaccines, needle-free intradermal immunization vaccines not only provide effective protection against specific diseases but also offer the following advantages: ①No risk of broken needles or injection abscesses, improving food safety and quality; ②Reduced risk of cross-infection from injection needles, enhancing biosecurity; ③Simple and convenient operation, improving labor efficiency; ④Reduced animal injection stress, enhancing the welfare of both personnel and animals; ⑤Environmentally friendly: Reducing cold chain storage space and the amount of waste generated.

Teng Feng, General Manager of Merck & Co., Inc. Animal Health ChinaMSD Animal Health adheres to the principle of "Science Makes Animals Healthier."^TM' concept, has been committed to providing innovative and high-quality health care and technological products for farm animals and pets. The needle-free intradermal immunization technology not only improves the efficiency and safety of vaccine injections but also has profound significance in ensuring food safety and animal welfare. We believe that Yuanleda^®The approval and market launch will provide a brand-new circovirus solution for China, the world's largest pig farming market, to help customers improve swine health, enhance breeding efficiency, and ensure the stable supply of safe and high-quality pork products to Chinese consumers.

       Yuan Le Da^®Is MSD Animal Health IDAL^®The first in the series to be registered in China as a needle-free intradermal immunization vaccine. MSD Animal Health will continue to develop and bring more IDAL products.^®Vaccines are introduced in China, with a product portfolio based on biopharmaceuticals and technical solutions, supporting the Chinese pig farming industry and continuously improving the shared well-being of humans and animals.

About MSD Animal Health

       MSD's goal is clear: to harness the power of cutting-edge science to save and improve the lives and health of people and animals worldwide. MSD is the corporate name of Merck & Co., Inc., headquartered in Rahway, New Jersey, USA. For over a century, it has been at the forefront of research and development, delivering medicines, vaccines, and innovative health solutions to address some of the world’s most challenging diseases. MSD Animal Health, MSD’s global animal health division, upholds the belief that "Science Makes Animals Healthier."^TM" philosophy, providing veterinarians, livestock farmers, producers, pet owners, and governments with a wide range of veterinary pharmaceuticals, vaccines, health management solutions and services, as well as a series of digital identification, traceability, and monitoring products. MSD Animal Health is committed to maintaining and improving the health, well-being, and condition of animals and their caregivers, heavily investing in R&D and the supply chain, with robust and comprehensive R&D resources and a modernized global supply chain. MSD Animal Health operates in over 50 countries and regions worldwide, with products covering more than 150 markets. For more information, please visit the MSD Animal Health headquarters website at www.msd-animal-health.com or follow MSD Animal Health's official social media accounts on LinkedIn and X.

About MSD Animal Health China

       China is a crucial part of MSD's global growth strategy. MSD Animal Health's China headquarters is located in Shanghai, with manufacturing facilities in Ningbo and Tianjin; the Ningbo site also hosts a research and development center. Currently, MSD Animal Health operates five major business divisions in China: pets, poultry, swine, ruminants, and aquaculture. The company offers more than 50 veterinary vaccines and pharmaceuticals, over 20 aquaculture products, as well as technological solutions for animal identification and behavior monitoring to enhance animal health, improve animal welfare, and benefit Chinese society. For more information, please visit MSD Animal Health China’s official website at https://www.msd-animal-health.com.cn/company/msd-china/ or follow MSD China's official WeChat account.

MSD Forward-Looking Statements

       MSD is the corporate name of Merck & Co., Inc., located in Rahway, New Jersey, USA (hereinafter referred to as "the Company"). This press release contains "forward-looking statements" made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The content herein is based on the current views and expectations of the Company’s management and is subject to significant risks and uncertainties. MSD does not guarantee that its products under development will receive the necessary regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties arise, actual results may differ materially from those anticipated in the forward-looking statements.

       Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors (including interest rate and currency fluctuations), the impact of pharmaceutical industry regulations and healthcare policies in the United States and other countries, global trends toward healthcare cost containment, technological advances, new products and patents obtained by competitors, inherent challenges in new product development (including obtaining regulatory approval), MSD's ability to accurately predict future market conditions, difficulties or delays in production, instability in international economic and financial conditions and sovereign risks, reliance on the effectiveness of MSD’s patent and other innovative product protections, and the risk of patent litigation and/or regulatory actions against the company.

       MSD has no obligation to publicly update any forward-looking statements due to new information, future events, or other reasons. Other factors may cause actual results to materially differ from forward-looking statements; see MSD's 2023 Annual Report on Form 10-K and other documents filed with the U.S. Securities Exchange Commission (available at www.sec.gov).